All In Biotech

Drug Trial Radar · NCT03230526

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

31

Actual

Start

Apr 16, 2018

Primary completion

May 6, 2024

Study completion May 6, 2024

Sponsor

Lead sponsor
Nantes University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 67 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II, Open-labeled, Prospective, Multi-center study of assessing the link between microglial activation and dopaminergic denervation kinetics in the early stage of Parkinson disease, by using the imaging of \[18F\]DPA-714 a new ligand of Translocator Protein-18 kDa (TSPO) by Positron Emission Tomography (PET).

Conditions

  • Parkinson Disease

Interventions

  • [18F]DPA-714 PET scanDrug

    One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23. Neuropsychological assessment is done at M0, M18 and M24

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Coefficient of correlation between level of microglial striatal activation and the And the dopaminergic denervation kineticsTime frame: 24 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de Nantes

    Nantes, France

  • Centre Eugène Marquis

    Rennes, France

  • CHU de Rennes

    Rennes, France

  • CHU de Tours

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.